CN104640563A - 包含嵌合的ospa分子的组合物及其使用方法 - Google Patents

包含嵌合的ospa分子的组合物及其使用方法 Download PDF

Info

Publication number
CN104640563A
CN104640563A CN201380048400.3A CN201380048400A CN104640563A CN 104640563 A CN104640563 A CN 104640563A CN 201380048400 A CN201380048400 A CN 201380048400A CN 104640563 A CN104640563 A CN 104640563A
Authority
CN
China
Prior art keywords
composition
borrelia
seq
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380048400.3A
Other languages
English (en)
Chinese (zh)
Inventor
诺尔·P·巴尔莱特
杰拉尔德·埃辛格尔
布莱恩·A·克洛维
伊安·利维
妮娜·弗雷瑟尼格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hundred Deep Co
Hundred Deep LLC
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN104640563A publication Critical patent/CN104640563A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380048400.3A 2012-07-27 2013-07-11 包含嵌合的ospa分子的组合物及其使用方法 Pending CN104640563A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676668P 2012-07-27 2012-07-27
US61/676,668 2012-07-27
PCT/US2013/050058 WO2014018274A1 (en) 2012-07-27 2013-07-11 Compositions comprising chimeric ospa molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
CN104640563A true CN104640563A (zh) 2015-05-20

Family

ID=48901170

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380048400.3A Pending CN104640563A (zh) 2012-07-27 2013-07-11 包含嵌合的ospa分子的组合物及其使用方法

Country Status (11)

Country Link
US (1) US9023367B2 (2)
EP (2) EP2877206B1 (2)
JP (1) JP2015524802A (2)
KR (2) KR20200068756A (2)
CN (1) CN104640563A (2)
AU (3) AU2013293448A1 (2)
CA (1) CA2879689A1 (2)
PL (1) PL2877206T3 (2)
RU (1) RU2015106742A (2)
SI (1) SI2877206T1 (2)
WO (1) WO2014018274A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106771250A (zh) * 2017-01-06 2017-05-31 杭州京北生物科技有限公司 一种用于检测哺乳动物莱姆病的荧光素酶免疫共沉淀试剂盒
CN107641151A (zh) * 2010-05-14 2018-01-30 百深公司 Ospa嵌合体及其在疫苗中的用途
CN115698044A (zh) * 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6405103B2 (ja) * 2014-03-18 2018-10-17 日本製粉株式会社 ソバアレルゲン特異的モノクローナル抗体
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CN119173446A (zh) 2022-03-08 2024-12-20 赤盾医疗有限公司 机器人药物制备系统中的流体转移站
IL325800A (en) 2023-07-10 2026-03-01 Dynavax Tech Corp Lyme disease vaccines containing adjuvant and Borrelia outer protein A antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143617A1 (en) * 2010-05-14 2011-11-17 Baxter International Inc. Chimeric ospa genes, proteins, and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0571538T5 (da) 1991-02-15 2002-03-04 Uab Research Foundation Strukturgen for pneumokokprotein
JPH07501687A (ja) 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
PT726955E (pt) 1993-11-01 2004-08-31 Brookhaven Science Ass Llc Proteinas quimericas compreendendo polipeptidos borrelia: suas utilizacoes
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
EP0880360B1 (en) 1996-02-12 2002-10-09 Cobra Therapeutics Limited Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6592875B1 (en) * 1999-06-21 2003-07-15 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
EP1939294A1 (en) 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
DK1311682T3 (da) 2000-08-18 2008-05-05 Univ New York State Res Found Rekombinante konstruktioner af Borrelia burgdorferi
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
WO2008101667A1 (en) 2007-02-22 2008-08-28 Baxter International Inc. Method of purification of hydrophobic proteins
EP2274616A1 (en) 2008-04-22 2011-01-19 The Research Foundation of State University of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143617A1 (en) * 2010-05-14 2011-11-17 Baxter International Inc. Chimeric ospa genes, proteins, and methods of use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107641151A (zh) * 2010-05-14 2018-01-30 百深公司 Ospa嵌合体及其在疫苗中的用途
CN106771250A (zh) * 2017-01-06 2017-05-31 杭州京北生物科技有限公司 一种用于检测哺乳动物莱姆病的荧光素酶免疫共沉淀试剂盒
CN115698044A (zh) * 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物

Also Published As

Publication number Publication date
US9023367B2 (en) 2015-05-05
WO2014018274A1 (en) 2014-01-30
EP2877206B1 (en) 2019-11-27
RU2015106742A (ru) 2016-09-20
CA2879689A1 (en) 2014-01-30
AU2020200708A1 (en) 2020-02-20
KR20200068756A (ko) 2020-06-15
EP2877206A1 (en) 2015-06-03
HK1208627A1 (en) 2016-03-11
WO2014018274A8 (en) 2015-03-12
SI2877206T1 (sl) 2020-07-31
EP3682897A1 (en) 2020-07-22
JP2015524802A (ja) 2015-08-27
AU2018203336B2 (en) 2019-10-31
AU2013293448A1 (en) 2015-02-05
PL2877206T3 (pl) 2020-12-14
KR20150038380A (ko) 2015-04-08
AU2018203336A1 (en) 2018-05-31
US20140030284A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CN103108652B (zh) 嵌合OspA基因、蛋白以及其使用方法
AU2018203336B2 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
HK1208627B (en) Compositions comprising chimeric ospa molecules and methods of use thereof
HK40029422A (en) Ospa chimeras and use thereof in vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160707

Address after: Swiss Aupu

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Illinois State

Applicant before: Baxter International Inc.

Applicant before: Baxter Healthcare S. A.

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150520

WD01 Invention patent application deemed withdrawn after publication